Our purpose, strategy and culture

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.

We are a company where outstanding people can thrive.

Our mission

Our strategy

GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company.

We prioritise innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.

Explore more on R&D on our global website 

Learn more about our partnerships at global level

Our portfolio

Vaccines help protect people from infectious diseases at every stage of life. Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more. Today, two million doses of our vaccines are administered daily, and 4 in 10 of the world’s children receive a GSK jab each year. We use diverse platform technologies from adjuvants that improve vaccine effectiveness through to mRNA technology. These are at the heart of our pipeline differentiation.

Belgium is home to the core of GSK's Vaccines division, with three major production sites in Wavre, Rixensart and Gembloux, as well as the international operations centre 'GSK Vaccines'. This represents the largest industrial network for vaccine production in the world.

Specialty products are prescribed by healthcare professionals in so-called specialty therapeutic areas. For GSK, these include products in the areas of infectious diseases and severe asthma. In addition, we offer life-changing cancer drugs. In addition, we offer medicines for immune diseases, including the first new medicine in 50 years for lupus, a chronic autoimmune disease from which more than 4000 Belgian patients suffer.

We are global leaders in developing medicines for HIV. Having pioneered the first HIV treatments in the 1980s, our goal now is to limit the impact of HIV on people’s lives by treating, preventing and ultimately curing it.

First-line medicines are generally prescribed by general practitioners. At GSK, these include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Every day, these medicines improve the health and lives of millions of people around the world. For more than 50 years, we have been helping millions of people with respiratory conditions to breathe easier, including the first inhalers in 1969. GSK in Belgium, with its portfolio of respiratory treatments, remains the industry leader.

Our therapeutic areas

RSV virus

Infectious diseases

Infectious diseases

Almost half the vaccines and medicines in our pipeline address infectious diseases, helping protect people from diseases like meningitis, shingles, flu, polio, measles and many more.

Visuel virus VIH



Our long-acting HIV medicines have the potential to dramatically change people’s experience by giving them an alternate to daily medicine.

Immunology illustration



We develop cancer medicines with life-changing potential for patients with ovarian cancer, endometrial cancer and multiple myeloma. We’ve accelerated this research and currently have three marketed therapies and a further nine assets in development.

Visuel lupus



Our focus on the science of the immune system helps us develop vaccines and medicines for a range of immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in 50 years.

DNA branch illustration

Opportunity-driven therapies

Opportunity-driven therapies

We also pursue other opportunity-driven therapies where the science aligns with our strategic approach. This includes the work we are doing to help the one in seven of the 700 million chronic kidney disease sufferers with anaemia.

Our long-term priorities


We’re uniting science, technology and talent to make a difference in more people’s lives. We don’t just want to find new, better medicines and vaccines. We’re working to get better at finding them in ways that are faster, more effective, and more predictable. This is reflected in the continued success of our R&D pipeline, which saw significant progress in 2021. Strategic partnerships are critical to opening up new avenues of discovery. We have important collaborations, including with the University of Oxford on neurodegenerative diseases, Kings College London on cancer treatment and 23andMe on genetics and genomics.

How we innovate

Facts and figures on R&D in Belgium

  • vaccine-candidates

  • euros investment in R&D in 2021

    1 billion
  • scientific collaborations with Belgian universities and research centers


Facts and figures on R&D worldwide

  • major approvals since 2017

  • potential new vaccines and medicines in Phase 3 and registration in 2017

  • vaccines and medicines in our pipeline


We’re confident in our future. Our bold ambitions for patients are reflected in new commitments to growth and a significant step-change in delivery over the next five years. This means more GSK vaccines and medicines, including innovative new products, will reach more people who need them than ever before. 

Facts and figures on performance in Belgium

  • of exported vaccines to > 160 countries in 2022

  • with more than 10% of all exports from Wallonia in 2022

    1st exporter

Facts and figures on performance worldwide

  • vaccines delivered in 2021

  • medicine doses delivered in 2021


Being a responsible business is an integral part of our strategy. We apply our strengths and take action in the areas that can most positively impact patients, society and our people over the long-term. This includes pricing and access, sustainability, global health and health security, diversity, equity and inclusion, product governance and operating standards.

In Belgium, we are committed to sustainability with initiatives to maintain a healthy planet for healthy people. Our mission is to have a net zero impact on the climate and a net positive impact on nature by 2030. We also want to be recognised for our inclusiveness, so we encourage and celebrate diversity. Respect and inclusion are an integral part of our corporate culture. GSK Belgium has been awarded the CAP48 award for Responsible Business in 2021.

Our Responsibility

Our culture

Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing are the foundations for how, together, we’ll deliver for our patients, shareholders and GSK people.

Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.